Investigational drug · Phase 2
ADX-914
Also called: bempikibart
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Alopecia Areata.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ADX-914"
First trial start
2022
Sep 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADX-914", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Alopecia Areata
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Alopecia areata · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ADX-914" as an intervention, largest first.
- Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)Pivotal-lookingActive, not recruiting
Q32 Bio Inc.Industry
NCT05509023 · 102 participants (planned) · Start Sep 30, 2022 · Primary completion Dec 2024
Drug: ADX-914; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 24 sites in all
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)Active, not recruiting
Q32 Bio Inc.Industry
NCT06018428 · 75 participants (planned) · Start Sep 12, 2023 · Primary completion Jun 2026
Drug: bempikibart (ADX-914) · For: Alopecia Areata
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Hot Springs, Arkansas · 33 sites in all
Q32 Bio Inc.Industry
NCT04485481 · 42 participants · Start Sep 8, 2020 · Primary completion Jan 12, 2022
Drug: ADX-914; Placebo and 2 more · For: Safety Issues
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.
Tang A, Rachko G, Manzo Margiotta F, et al. · J Inflamm Res 2026
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.